Takeaway
- The RATIONALE-303 trial of the experimental drug tislelizumab found 34%-47% improvement in OS over docetaxel in a phase 3 trial of pretreated patients with advanced NSCLC.
Why this matters
- The findings will be used in the new drug application of tislelizumab, which is an anti-programmed cell death-1 (PD-1) immunoglobulin...